Trial Profile
Resistance to ErythroPoietin Effectiveness Algorithm Trial.
Status:
Discontinued
Phase of Trial:
Phase III
Latest Information Update: 03 Oct 2021
Price :
$35
*
At a glance
- Drugs Epoetin alfa (Primary)
- Indications Refractory anaemia
- Focus Therapeutic Use
- Acronyms REPEAT
- 19 Feb 2009 New trial record